This webinar will delve into the revolutionary field of CAR-T cell therapy, exploring its impact in crucial areas such as history and principles, manufacturing processes, and its diverse range of clinical applications.
CAR-T cell therapy has emerged as a groundbreaking immunotherapy, holding immense promise in the treatment of various diseases, particularly hematologic malignancies. Understanding the core principles and historical context of CAR-T therapy is vital in comprehending its evolution and success.
1. History and Principles:
By delving into the historical perspectives of CAR-T cell therapy, we aim to provide participants with a comprehensive understanding of its development and evolution. From the early concepts to the groundbreaking achievements, this segment will showcase the journey of CAR-T therapy and its transformation into a cutting-edge treatment modality.
The manufacturing process plays a pivotal role in CAR-T therapy, influencing its efficacy and safety. We will highlight the complexities and innovations in CAR-T cell production, emphasizing the importance of quality control and standardization in ensuring the therapeutic success of CAR-T treatments.
3. Clinical Applications:
The clinical applications of CAR-T therapy have expanded rapidly, encompassing a wide range of diseases and patient populations. In this segment, we will explore the latest clinical advancements and successes of CAR-T therapy, discussing its impact on patient outcomes and its potential to revolutionize medical practices.
The importance of this webinar lies in the transformative potential of CAR-T cell therapy and its ability to bring about positive changes in patients' lives. This is exemplified by research studies, which explored the influence of social determinants of health on CAR-T therapy outcomes for young patients with relapsed/refractory B-acute lymphoblastic leukemia (B-ALL)/lymphoma.
This reinforces the need for equitable and accessible healthcare systems, so that vulnerable populations can benefit from the advancements in CAR-T therapy as well in South and central America.
Desiree Kosan, MS, RN, OCN
CAR-T Cell Collections Manager
Janssen Pharmaceutical Companies of Johnson & Johnson